Paul Coletta Of Vero Bioscience Talks Fundraising, Ai On The Disrupt By Athletech News Podcast
Paul Coletta joins the show to explore the rise of longevity-focused businesses and how they’re shaping the future of the fitness and wellness industry
In the latest episode of Disrupt by Athletech News, Vero Bioscience co-founder and CEO Paul Coletta joins ATN founder and CEO Edward Hertzman with Eric Malzone to share insights from his experience building and leading a growing longevity brand. The three discuss the new kinds of investors in wellness, why organ maintenance is the key to improving healthspan and the data overload issue with consumers.
The three also touch on the impact influencers can make on your business, their takeaways from recent longevity-focused events, and why AI will continue to support clinicians rather than replace them.
Listen to this episode of Disrupt for more on:
- Unlocking a new science vs monetizing off people’s anxieties in longevity
- Brand appreciation beating market size
- Longevity business fundraising best practices
Key Talking Points:
- (0:00 – 9:44) Longevity at Eudēmonia
- (12:25 – 19:48) Inside Vero Bioscience’s business proposition
- (19:48 – 23:17) Where AI meets longevity
- (23:17 – 26:48) You lifestyle choices are most important
- (26:48 – 35:42) Who’s investing in longevity and why
- (35:42 – 42:54) How to work with Vero
- (42:54 – 46:52) Wrap up
Accept marketing cookies to view this content.
More from ATN
- Just Released: Athletech’s Franchise Outlook Report
- From Hyrox to Bathhouses: Key Takeaways as Wellness Economy Hits $7.5T
- New Startups Push to Innovate Strength Training Tech
- ATHX Games Unveils USA vs Europe Competition
- Want the industry edge? Join ATN Pro for unlimited access, exclusive analysis and event perks.